title: Cilengitide Merck.
abstract: Merck KGaA is developing cilengitide, the lead in a series of integrin antagonists with anti-angiogenic activities, for the potential treatment of a variety of cancer types. The National Cancer Institute is conducting clinical trials of cilengitide. In October 1999, phase II trials in non-small-cell lung cancer (as a monotherapy) and pancreatic cancer (in combination with gemcitabine) were initiated. These were ongoing in February 2002, by which time, a phase I trial and a phase I/II trial in glioblastoma were underway.
authors.affiliation: Burnham Institute, 10901 N Torrey Pines Road, La Jolla, CA 92037-1005, USA. jsmith@burnham.org
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Smith
mesh_terms: D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D012910:Snake Venoms / Q000138:chemical synthesis / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D015507:Drugs, Investigational; D012910:Snake Venoms; C422910:Cilengitide